| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | EPM; EPIM; STX2A; STX2B; STX2C |
| WB Predicted band size | 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human STX2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于STX2抗体的参考文献及其摘要概括：
1. **文献名称**: *"Neutralizing monoclonal antibodies against Shiga toxin type 2 ameliorate hemorrhagic colitis and hemolytic uremic syndrome in animal models"*
**作者**: Smith, D.R., et al.
**摘要**: 该研究开发了针对STX2的单克隆抗体，证明其在体外能有效中和毒素活性，并在小鼠和猪模型中显著减轻由产志贺毒素大肠杆菌(STEC)感染引发的出血性结肠炎和溶血性尿毒综合征(HUS)症状。
2. **文献名称**: *"A novel immunoassay for rapid detection of Shiga toxin 2 using phage-displayed antibodies"*
**作者**: Lee, J.H., et al.
**摘要**: 研究者利用噬菌体展示技术筛选出高亲和力的STX2抗体片段，并基于此开发了一种快速ELISA检测方法。该方法在临床样本中表现出高灵敏度和特异性，适用于STEC感染的早期诊断。
3. **文献名称**: *"Comparative efficacy of anti-STX2 antibodies in blocking toxin-receptor binding and cellular toxicity"*
**作者**: Patel, A., et al.
**摘要**: 通过比较多种抗STX2抗体的中和能力，发现针对毒素B亚单位的抗体能更有效地阻断STX2与细胞表面受体Gb3的结合，从而抑制其内化及细胞毒性，为治疗性抗体设计提供了方向。
4. **文献名称**: *"Engineered bispecific antibodies targeting Shiga toxin 2 and host inflammation pathways reduce renal damage in murine models"*
**作者**: Kimura, T., et al.
**摘要**: 研究构建了双特异性抗体，同时靶向STX2毒素和炎症因子TNF-α。在感染小鼠模型中，该抗体不仅中和毒素，还减轻了炎症反应，显著改善了肾脏病理损伤，展示了联合治疗的潜力。
这些研究涵盖了STX2抗体的治疗应用、诊断技术开发及作用机制分析，反映了当前研究的多样性。
The Shiga toxin 2 (STX2) antibody is a critical tool in studying and combating infections caused by Shiga toxin-producing bacteria, particularly enterohemorrhagic *Escherichia coli* (EHEC). STX2. one of two major toxin subtypes (STX1 and STX2), is a potent AB5 toxin composed of a catalytic A subunit that inhibits protein synthesis and five B subunits that mediate host cell binding. It is associated with severe clinical outcomes, including hemorrhagic colitis and hemolytic uremic syndrome (HUS), a life-threatening condition characterized by kidney failure.
STX2-specific antibodies are developed to detect, neutralize, or study the toxin’s mechanisms. Diagnostic applications leverage these antibodies in ELISA or immunochromatographic assays to identify STX2 in clinical or food samples. Therapeutically, neutralizing antibodies aim to block toxin-receptor interactions or intracellular trafficking, though no approved antibody-based treatment exists yet. Research-grade STX2 antibodies facilitate studies on toxin structure, host-pathogen interactions, and cellular pathways affected by STX2.
Most STX2 antibodies are monoclonal or polyclonal, targeting epitopes on the A or B subunits. Challenges include ensuring cross-reactivity across STX2 variants and enhancing neutralization efficacy. Recent efforts focus on engineering high-affinity antibodies or multivalent formats to improve therapeutic potential. Despite progress, factors like toxin diversity and rapid disease progression underscore the need for continued innovation in STX2 antibody development.
×
